Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Cel-Sci completes another study in head and neck cancer

Dec. 29, 1999

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Dec. 29, 1999

Biomira's BLP25 liposome technology offers promise as cancer therapy

Dec. 29, 1999

SuperGen acquires equity interest in AVI BioPharma and negotiating rights to Avicine

Dec. 28, 1999

BLA filing for Campath announced

Dec. 27, 1999

AVI BioPharma's cancer vaccine enters phase III development

Dec. 27, 1999

DSMB recommends continuation of Allovectin-7 trials

Dec. 23, 1999

CeaVac trial reaches accrual goal; phase II trial will be expanded to phase III

Dec. 23, 1999

Transgene presents phase II data for cancer vaccine

Dec. 23, 1999

StressGen's new treatment for cervical dysplasia successfully completes phase I study

Dec. 14, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...